Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Epacadostat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Complete response rate in Nektar melanoma trial hits 34%
    Complete response rate in Nektar melanoma trial hits 34%

    04 Jun 2019

    // Nick P. Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/complete-response-rate-nektar-melanoma-trial-hits-34

    Nick P. Taylor FIERCE BIOTECH
    04 Jun 2019
    Share Share
    OncoSec announces triple combo trial of TAVO, Epacadostat & Keytruda
    OncoSec announces triple combo trial of TAVO, Epacadostat & Keytruda

    24 Apr 2019

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=115411&sid=2

    PHARMABIZ
    24 Apr 2019
    Share Share
    Nektar's Sole Skeptic Warns of Parallels to Biggest Biotech Flop
    Nektar's Sole Skeptic Warns of Parallels to Biggest Biotech Flop

    05 Jun 2018

    // Tatiana Darie BLOOMBERG

    https://www.bloomberg.com/news/articles/2018-06-05/nektar-s-sole-skeptic-warns-of-parallels-to-biggest-biotech-flop

    Tatiana Darie BLOOMBERG
    05 Jun 2018
    Share Share